If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » Marketing Management » Designing Marketing Strategies » Product Positioning and Differentiation
Download FREE Excerpt
13 Info Graphics
3 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Cetuximab – marketed as “Erbitux” – won its initial US approval in 2004 and by 2006 became a blockbuster oncology product. After its approval in 2004 for colorectal cancer and in 2006 for head and neck cancer, Erbitux became a frequent subject of presentations at key scientific congresses. ImClone and partner BMS used the presentations to inform the oncology community about the clinical success of Erbitux in treating two difficult to treat cancers. Now Eli Lilly, following its 2008 acquisition of ImClone, continues to use congresses such as the American Society of Clinical Oncology to keep oncologists abreast of the therapy’s progress in studies involving other types of cancer.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.